With a poison pill provision and staggered Board elections, Illumina seems to be well-protected from unruly suitors during a time when its stock price is so undervalued. So, how will Roche win the chess match with Illumina’s Board and its shareholders?
From the NY Times Blog, a fascinating and well researched portrayal of why there is an obvious chink in the armor at Illumina and how Roche will ultimately win out. As detailed in our last post, Roche is a veteran at these moves, having won longstanding struggles with Ventana & Genentech.
Want to know why? Here are the details regarding corporate structure that will lead Roche to prevail.
